492 related articles for article (PubMed ID: 38201290)
1. miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.
Huang W; Paul D; Calin GA; Bayraktar R
Cells; 2023 Dec; 13(1):. PubMed ID: 38201290
[TBL] [Abstract][Full Text] [Related]
2. MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies.
Damanti CC; Gaffo E; Lovisa F; Garbin A; Di Battista P; Gallingani I; Tosato A; Pillon M; Carraro E; Mascarin M; Elia C; Biffi A; Bortoluzzi S; Mussolin L
Cells; 2021 Jan; 10(1):. PubMed ID: 33429910
[TBL] [Abstract][Full Text] [Related]
3. Exosomal microRNA panels as biomarkers for hematological malignancies.
Moloudizargari M; Hekmatirad S; Mofarahe ZS; Asghari MH
Curr Probl Cancer; 2021 Oct; 45(5):100726. PubMed ID: 33752898
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between microRNA-155 and hematological malignancies].
Xue H; Hua LM; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):810-4. PubMed ID: 23815946
[TBL] [Abstract][Full Text] [Related]
5. Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.
Gaál Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628648
[TBL] [Abstract][Full Text] [Related]
6. The role of miR-29 family members in malignant hematopoiesis.
Kollinerova S; Vassanelli S; Modriansky M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):489-501. PubMed ID: 24993745
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.
Yoshizawa S; Umezu T; Saitoh Y; Gotoh M; Akahane D; Kobayashi C; Ohyashiki JH; Ohyashiki K
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142940
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic applications of miRNA-based technology in hematological malignancies.
Barbarotto E; Calin GA
Curr Pharm Des; 2008; 14(21):2040-50. PubMed ID: 18691114
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures.
Ji H; Chen M; Greening DW; He W; Rai A; Zhang W; Simpson RJ
PLoS One; 2014; 9(10):e110314. PubMed ID: 25330373
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs in normal and malignant hematopoiesis.
Garzon R; Croce CM
Curr Opin Hematol; 2008 Jul; 15(4):352-8. PubMed ID: 18536574
[TBL] [Abstract][Full Text] [Related]
12. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein.
Ghosh S; Bhowmik S; Majumdar S; Goswami A; Chakraborty J; Gupta S; Aggarwal S; Ray S; Chatterjee R; Bhattacharyya S; Dutta M; Datta S; Chowdhury A; Dhali GK; Banerjee S
Int J Cancer; 2020 Nov; 147(10):2934-2947. PubMed ID: 32441313
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies.
Dzikiewicz-Krawczyk A
Crit Rev Oncol Hematol; 2015 Jan; 93(1):1-17. PubMed ID: 25217091
[TBL] [Abstract][Full Text] [Related]
14. The miR-29 family in hematological malignancies.
Fiserova B; Kubiczkova L; Sedlarikova L; Hajek R; Sevcikova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):184-91. PubMed ID: 25004911
[TBL] [Abstract][Full Text] [Related]
15. Diabetes induces dysregulation of microRNAs associated with survival, proliferation and self-renewal in cardiac progenitor cells.
Purvis N; Kumari S; Chandrasekera D; Bellae Papannarao J; Gandhi S; van Hout I; Coffey S; Bunton R; Sugunesegran R; Parry D; Davis P; Williams MJA; Bahn A; Katare R
Diabetologia; 2021 Jun; 64(6):1422-1435. PubMed ID: 33655378
[TBL] [Abstract][Full Text] [Related]
16. DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.
Hu T; Chong Y; Cai B; Liu Y; Lu S; Cowell JK
J Biol Chem; 2019 Nov; 294(48):18122-18130. PubMed ID: 31628193
[TBL] [Abstract][Full Text] [Related]
17. The role of microRNAs in normal and malignant hematopoiesis.
Vasilatou D; Papageorgiou S; Pappa V; Papageorgiou E; Dervenoulas J
Eur J Haematol; 2010 Jan; 84(1):1-16. PubMed ID: 19744129
[TBL] [Abstract][Full Text] [Related]
18. Hematological malignancies: role of miRNAs and their in silico aspects.
Omer A; Yadav NK; Singh P; Singh RK
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1121-33. PubMed ID: 24053209
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as regulators of mammalian hematopoiesis.
Chen CZ; Lodish HF
Semin Immunol; 2005 Apr; 17(2):155-65. PubMed ID: 15737576
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis and microRNA expression profiling of plasma-derived exosomes in primary immune thrombocytopenia.
Sun Y; Hou Y; Meng G; Han P; Zhao Y; Wang H; Xu M; Wang Y; Qiu J; Peng J; Shao L; Sun L; Hou M
Br J Haematol; 2021 Sep; 194(6):1045-1052. PubMed ID: 34337736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
